Immunologically useful arginine salts
The invention is in the field of salt forms of an immunopotentiator compound and their formulation for in vivo use. In particular the invention relates to arginine salts.
1. An arginine salt of 3-(5-amino-2-(2-methyl-4-(2-(2-(2-phosphonoethoxy)ethoxy)ethoxy)phenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid.
2. The salt of claim 1 , wherein the salt has a 1:1 stoichiometry of arginine to 3-(5-amino-2-(2-methyl-4-(2-(2-(2-phosphonoethoxy)ethoxy)ethoxy)phenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid.
3. The salt of claim 1 , wherein the arginine salt is an L-arginine salt.
4. The salt of claim 1 , wherein the salt is hydrated.
5. The salt of claim 1 , wherein the salt is a monohydrate.
6. The salt of claim 1 , wherein the salt is a substantially amorphous solid.
7. A method of raising an immune response in a subject comprising administering to the subject a therapeutically effective amount of a salt of claim 1 .
8. A process for the preparation of the arginine salt of claim 1 , comprising the step of contacting 3-(5-amino-2-(2-methyl-4-(2-(2-(2-phosphonoethoxy)ethoxy)ethoxy)phenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid with arginine in an solvent.
9. A composition comprising an arginine salt of 3-(5-amino-2-(2-methyl-4-(2-(2-(2-phosphonoethoxy)ethoxy)ethoxy)phenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid and an insoluble metal salt.
10. The composition of claim 9 , further comprising an immunogen.
11. A process for preparing an adjuvant complex, comprising a step of mixing an arginine salt of 3-(5-amino-2-(2-methyl-4-(2-(2-(2-phosphonoethoxy)ethoxy)ethoxy)phenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid with an insoluble metal salt such that the acid adsorbs to the insoluble metal salt to form the complex.
12. A compound of (Ia):
or an arginine salt or solvate thereof.
13. An L-arginine salt of 3-(5-amino-2-(2-methyl-4-(2-(2-(2-phosphonoethoxy)ethoxy)ethoxy)phenethyl)benzo[1,7]naphthyridin-8-yl)propanoic acid having a 1:1 stoichiometry of arginine to 3-(5-amino-2-(2-methyl-4-(2-(2-(2-phosphonoethoxy)ethoxy)ethoxy)phenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid.
14. The salt of claim 13 , wherein the salt is hydrated.
15. The salt of claim 13 , wherein the salt is a monohydrate.
16. The salt of claim 13 , wherein the salt is a substantially amorphous solid.
17. A method of raising an immune response in a subject comprising administering to the subject a therapeutically effective amount of a salt of claim 2 .